

Isodiol International Inc.

11:04 19 Aug 2019

Buds & Duds: Cannabis stocks flat but Valens shares on the rise as it uplists to OTCQX Best Market

Cannabis stocks had a lacklustre start to Monday, with stocks fairly flat across North American markets.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was flat at 197.26 points. The Horizons Marijuana Life Sciences Index ETF was down 1% to C\$15.45. The OTCQX Cannabis Index was up 0.2% at 676.9 points.

Buds

Valens GroWorks Corp (CVE:VGW) (OTCMKTS:VGWCF) stock was on the rise after its shares started trading on the OTCQX Best Market on Monday having graduated from the OTCQB Market. The stock will begin trading under the ticker symbol VGWCF.

Valens shares were up 2.2% at C\$3.71 in Toronto, up 1.1% at US\$2.79 in New York.

"We are excited to begin trading on the OTCQX Best Market. Access to trading on OTCQX, combined with the current work underway to finalize the company's DTC eligibility, will increase Valens' presence with United States investors, providing increased liquidity to the company's growing shareholder base," says Tyler Robson, Valens CEO.

READ: Valens GroWorks shares to begin trading on OTCQX Best Market
The Flowr Corporation (CVE:FLWR) (OTCMKTS:FLWPF) shares were also gaining Monday. On Thursday, the firm released news that it continued to ramp up production in 2Q, while also advancing development at its flagship Kelowna Campus.

Shares were up 1.7% at 2.95 in Toronto.

For the second quarter ended June 30 2019, the company posted gross revenue of \$2.8 million and net revenue of \$2.2 million, which excludes \$358,000 in design and construction fees from Hawthorne Canada Limited linked to the construction of the R&D facility on the company's Kelowna Campus.

"We delivered an increase in production as we continue to optimize our operational grow rooms and were able to translate the production increase into a similar percentage increase in sales volumes," said CEO Vinay Tolia in a statement. "Revenues and average selling prices in the quarter were impacted by our product mix, predominantly as we sold fewer pre-rolls than in the prior quarter."

READ: Flowr Corp ramps up production and pushes flagship Kelowna campus forward in 2Q
Shares of CBD manufacturer Isodiol International Inc (CSE:ISOL) (OTCQB:ISOLF) were soaring Monday, up 36.5% to US\$0.40 in US trading after it released its 4Q and fiscal year results, ended March 31, 2019.

Price: 0.055

Market Cap: \$2.69 m

1 Year Share Price Graph



August 2019 February 2020 July 2020

Share Information

Code: ISOL

Listing: CSE

52 week	High	Low
	0.57	0.05

Sector: Cannabis

Website: isodiol.com

Company Synopsis:

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.

action@proactiveinvestors.com

For fiscal 2019, the firm reported revenue of \$22.25 million, a boost of 16.3% year over year. Its 4Q revenue came in at \$9.1 million.

"We have just realized our most profitable quarter to date and have reduced our operating expenses considerably, which will be seen in the first quarter of FY2020," said CEO Marcos Agramont. "The majority of losses experienced in FY 2019 are a by-product of our shift in our focus towards higher-margin consumer products vs raw ingredient supply, prevention of massive shareholder dilution and protecting our future cash flows through divestitures." Marcos went on, "Over the last several months we have sharpened our focus significantly, cut costs, curbed shareholder dilution and we believe the company is in a strong position heading into FY2020 and beyond."

Duds

CannTrust Holdings Inc (TSE:TRST) (NYSE:CTST) shares continued to lag Monday, after the firm released news that the Ontario Cannabis Store returned all of the company's products, as it deemed to be 'non-conforming product.' The company says the total value of the products is about C\$2.9 million.

Shares dropped 2.5% to C\$2.72 in Toronto, and were down 2.4% at US\$2.05 in New York.

"The (store) operates independently of Health Canada. Health Canada has not ordered a recall in respect of any of the company's products," noted CannTrust in a statement.

CannTrust has been embroiled in a scandal since early July after Health Canada found it was growing cannabis in unlicensed rooms at its Pelham, Ontario facility and later raised issues about its manufacturing facility in Vaughan, Ontario.

Also lagging Monday was Canopy Growth Corporation (TSE:WEED) (NYSE:CGC), a week after the firm announced its 1Q earnings, reporting a net loss of nearly \$1.3 billion as higher expenses offset revenue growth in the first quarter.

Shares were down 3.9% at US\$27.02 in New York, down 3.6% at C\$35.91 in Toronto.

The stock has dropped around 25% since releasing its earnings that missed analysts estimates by a wide margin.

Canopy reported Wednesday it lost \$1.28 billion for the quarter ended June 30, its fiscal first quarter of 2020, compared with a loss of \$91 million in the first quarter of fiscal 2019.

Contact Katie Lewis at katie@proactiveinvestors.com

Follow her on Twitter: [@kelewis](https://twitter.com/kelewis)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.